gliclazide and glucagon-like peptide 1

gliclazide has been researched along with glucagon-like peptide 1 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hayakawa, M; Matsuyama-Yokono, A; Nakano, R; Shibasaki, M; Shiraki, K; Someya, Y; Tahara, A1
Jermendy, G1
Bien, Z; Heald, AH; Laing, I; Livingston, M; Moreno, GYC; Stedman, M1

Reviews

1 review(s) available for gliclazide and glucagon-like peptide 1

ArticleYear
[Incretin-based therapy for treating patients with type 2 diabetes].
    Orvosi hetilap, 2011, Nov-27, Volume: 152, Issue:48

    Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin

2011

Other Studies

2 other study(ies) available for gliclazide and glucagon-like peptide 1

ArticleYear
Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Metabolism: clinical and experimental, 2009, Volume: 58, Issue:3

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gliclazide; Glucagon-Like Peptide 1; Glucose Intolerance; Glyburide; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred ICR; Niacinamide; Piperidines; Pyrrolidines; Sulfonylurea Compounds

2009
The pattern of prescribing of glucose modulating agents for type 2 diabetes in general practices in England 2016/17.
    International journal of clinical practice, 2018, Volume: 72, Issue:4

    Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Drug Prescriptions; England; Exenatide; General Practice; Gliclazide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Practice Patterns, Physicians'; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Venoms

2018